You are here: Industry Insights > HCV

News List

USPSTF Advises Broader Age Range for Hep C Screening drugs
August 28, 2019
The U.S. Preventive Services Task Force recommends hepatitis C virus (HCV) infection screening for individuals aged 18 to 79 years.
DAAs Cut Deaths in Those Treated for HCV-Related Liver Cancer drugs
August 21, 2019
Among patients with hepatitis C virus (HCV) infection and complete response to hepatocellular carcinoma (HCC) treatment, direct-acting antiviral (DAA) therapy is associated with a significant reduction in the risk for death...
Successful kidney transplants from hepatitis C infected individuals europeanpharmaceuticalreview
April 22, 2019
Transplantation followed by antiviral therapy cured hepatitis C in 100 percent of patients receiving kidneys from infected donors…
CDC: Proportion of Increased-Risk Deceased Organ Donors on Rise drugs
January 25, 2019
Among deceased organ donors, there has been an increase in the proportion at increased risk for transmitting hepatitis B virus (HBV).....
Many New Cancer Patients Unaware of Their Hepatitis Status drugs
January 23, 2019
A substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are unaware of their viral infection at the time of cancer diagnosis...
Appalachia, Western States Have Highest Hep C Prevalence drugs
December 27, 2018
States in the West and in Appalachia have a higher prevalence of hepatitis C virus (HCV) infection than other states, according to a study published online Dec. 21 in JAMA Network Open......
AbbVie sues NHS over hep C drug procurement scheme pharmaphorum
November 22, 2018
American pharma firm AbbVie is taking NHS England to court over a procurement process aimed to help England become the first country in the world to eradicate the hepatitis C virus (HCV).
Novartis' Promacta cleared by FDA for first-line use in severe aplastic anaemia pharmafile
November 20, 2018
Novartis has secured expanded approval from the FDA for Promacta (eltrombopag), allowing it to now be used in combination with standard immunosuppressive therapy (IST) for the first-line treatment of severe aplastic anaemia (SAA).
Gilead raises outlook despite dip in revenue pharmatimes
November 01, 2018
Gilead's revenue beat analysts' expectations in Q3 2018, despite falling behind last year's results, leading the company to boost its earnings expectations for the year.
Gilead to launch generic versions of hepatitis C drugs pharmaceutical-technology
September 27, 2018
Gilead Sciences has revealed plans to introduce generic versions of its Epclusa and Harvoni in the US for the treatment of chronic hepatitis C virus infection.

Previous page 1 2 3 4 Next page